Outlook Remains Positive with New Licensing Agreements and Successful Product Launches - Research Report on Restoration Life Technologies, Thermo Fisher, Agilent, Quest and PerkinElmer

NEW YORK, June 26, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Life Technologies Corporation (NASDAQ: LIFE), Thermo Fisher Scientific, Inc. (NYSE: TMO), Agilent Technologies Inc. (NYSE: A), Quest Diagnostics Inc. (NYSE: DGX) and PerkinElmer Inc. (NYSE: PKI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Life Technologies Corporation Research Report

On June 19, Life Technologies Corporation (Life Technologies) announced a new licensing agreement granting Suzhou Ribo Life Sciences (Ribo) exclusive rights to develop and manufacture siRNA therapeutics in China by using its Invivofectamine Rx delivery technology. Ribo will formulate proprietary siRNA molecules in combination with Invivofectamine Rx to create a new platform, designed to address human diseases with high unmet medical need in the Chinese healthcare system. Alan Sachs, M.D., Ph.D., Chief Scientific Officer and Head of Global Research at Life Technologies said, "In our continued effort to deliver game-changing products and technologies to the world's top medical researchers, we are pleased to partner with Dr. Liang and Suzhou Ribo Life Sciences. Invivofectamine Rx is a great example of the type of technology we will continue to license around the world as we expand our commitment to clinical research customers." The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/d9de_LIFE]

--

Thermo Fisher Scientific, Inc. Research Report

On June 10, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) launched the Thermo Scientific Orbitrap Fusion Tribrid liquid chromatography-mass spectrometry (LC-MS) system, which combines its three mass analyzers -quadrupole, Orbitrap and linear ion trap in a novel "Tribrid" architecture, and offers unprecedented depth of analysis of complex biological samples. "Our mission has been to create the highest-performing commercial mass spectrometer ever built," said Dr. Ian Jardine, Chief Technology Officer, Chromatography and Mass Spectrometry, Thermo Fisher Scientific. "Additionally, we wanted to make this power widely accessible to the science community and make it incredibly easy to use. In creating the Orbitrap Fusion, we have combined and improved our quadrupole, linear ion trap and Orbitrap technologies in an ultimately flexible research MS system - to arrive at an entirely new class of instrument that will transform our customers' science." The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/45ea_TMO]

--

Agilent Technologies Inc. Research Report

On June 21, 2013, Agilent Technologies Inc. (Agilent) introduced the U5303A, a compact dual-channel PCle digitizer with 12-bit resolution which delivers unprecedented analog fidelity, high effective number of bits and very low noise. "By coupling high resolution with high precision, the U5303A is one of the best products in its class," said Didier Lavanchy, Operation Manager for Agilent's high-speed digitizers. "Its development leverages innovations that were first introduced in the 12-bit AXIe digitizer, which was named a 2013 Best in Test winner by Test & Measurement World magazine." The Company informed that the U5303A two-channel, 12-bit, high-speed PCIe high-speed digitizer with on-board processing is now available for ordering. The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/075f_A]

--

Quest Diagnostics Inc. Research Report

On June 6, 2013, Quest Diagnostics Inc. (Quest) announced that President and Chief Executive Officer Steve Rusckowski reaffirmed the Company's guidance for its results from continuing operations, before special items, for full-year 2013. Accordingly, he affirmed that the Company expects revenues to approximate the prior-year level; earnings per diluted share to be between $4.35 and $4.55; cash provided by operations to approximate $1 billion; and capital expenditures to approximate $250 million during full-year 2013. Mr. Rusckowski stated, "We remain comfortable with our guidance for the full-year 2013 as we are making good progress on all five points of our business strategy. As we've said, 2013 is a building year and we expect to see improvements in revenues and earnings versus the prior year starting in the second half. Second quarter revenues and earnings are expected to be down versus the prior year, but improved compared to first quarter results." The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0cb6_DGX]

--

PerkinElmer Inc. Research Report

On June 10, 2013, PerkinElmer Inc. (PerkinElmer) introduced the AxION iQT gas chromatography tandem mass spectrometer (GC/MS/MS) at the 2013 American Society for Mass Spectrometry Conference. According to the Company, the new mass spectrometer provides laboratories with easier to use technology, faster results, and more specific, selective data needed to make more accurate decisions faster. "Global regulatory expansion is driving increased adoption of mass spectrometry as the technology provides greater sample insights for many industries," said Dusty Tenney, President of Environmental Health at PerkinElmer. "We've created a new category of mass spectrometry designed to be faster, smarter, modular and easy to operate and maintain that combines superior quantitative and identification performance into one instrument, making this latest generation of technology both user and budget friendly." The Full Research Report on PerkinElmer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2d16_PKI]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports